| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,244,684 |
4,978,018 |
| Total Buy Value |
$0 |
$0 |
$24,978,318 |
$65,978,328 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
225,453 |
235,538 |
246,104 |
4,525,329 |
| Total Sell Value |
$3,837,225 |
$3,955,119 |
$4,100,690 |
$62,122,635 |
| Total People Sold |
4 |
4 |
4 |
8 |
| Total Sell Transactions |
14 |
18 |
25 |
103 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blackman Samuel C. |
Head of Research and Developme |
• – – |
2023-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,238,943 |
|
- |
|
| Dubow Adam |
General CounselOfficer |
• – – |
2023-11-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,141 |
|
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2023-10-20 |
4 |
B |
$9.97 |
$1,110,907 |
D/D |
111,387 |
12,929,322 |
2.44 |
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2023-10-19 |
4 |
B |
$10.06 |
$3,867,372 |
D/D |
384,400 |
12,817,935 |
2.44 |
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2023-10-18 |
4 |
B |
$10.21 |
$10,000,049 |
D/D |
979,667 |
12,433,535 |
2.44 |
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-08-17 |
4 |
S |
$13.86 |
$41,525 |
D/D |
(2,996) |
704,224 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-08-17 |
4 |
S |
$13.86 |
$12,779 |
D/D |
(922) |
267,501 |
|
- |
|
| Blackman Samuel C. |
Head of Research and Developme |
• – – |
2023-08-17 |
4 |
S |
$13.86 |
$9,258 |
D/D |
(668) |
1,236,319 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,312 |
707,220 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,625 |
268,423 |
|
- |
|
| Blackman Samuel C. |
Head of Research and Developme |
• – – |
2023-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,236,987 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-07-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
570,251 |
270,226 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-07-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
329,963 |
251,636 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-07-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
240,288 |
698,908 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
240,288 |
240,288 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-07-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(240,288) |
939,196 |
|
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2023-06-09 |
4 |
B |
$13.00 |
$9,999,990 |
D/D |
769,230 |
11,453,868 |
2.44 |
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-06-05 |
4 |
AS |
$16.00 |
$19,664 |
D/D |
(1,229) |
1,234,363 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-05-16 |
4 |
S |
$13.12 |
$40,732 |
D/D |
(3,104) |
1,179,484 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-05-16 |
4 |
S |
$13.12 |
$9,081 |
D/D |
(692) |
1,235,592 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-05-16 |
4 |
S |
$13.12 |
$12,532 |
D/D |
(955) |
264,798 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2023-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,312 |
1,182,588 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,236,284 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2023-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,625 |
265,753 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2023-03-10 |
4 |
AS |
$18.05 |
$180,484 |
D/D |
(10,000) |
1,233,660 |
|
- |
|
174 Records found
|
|
Page 2 of 7 |
|
|
